Table 1

Demographics and clinicopathologic characteristics of the training cohort and the testing cohort

CharacteristicsEntire cohort
(N=240)
Training cohort (N=171)P valueTesting cohort (N=69)P value
Non-response
(N=110)
Response
(N=61)
Non-response
(N=45)
Response
(N=24)
Age0.2940.139
Mean±SD48.36±10.3847.56±10.8249.32±9.8247.49±9.7951.29±10.53
Age group0.3980.713
 <4053 (22.1)27 (24.5)13 (21.3)9 (20.0)4 (16.7)
40–5077 (32.1)37 (33.6)16 (26.2)17 (37.8)7 (29.2)
≥50110 (45.8)46 (41.8)32 (52.5)19 (42.2)13 (54.2)
BMI (kg/m²)0.9460.818
Mean±SD22.91±3.2323.01±3.3622.98±3.3622.76±3.2922.59±2.27
BMI group0.7880.569
<18.522 (9.2)10 (9.1)7 (11.5)4 (8.9)1 (4.2)
18.5–24133 (55.4)59 (53.6)34 (55.7)24 (53.3)16 (66.7)
 >2485 (35.4)41 (37.3)20 (32.8)17 (37.8)7 (29.2)
ECOG performance status0.1851.000
0–1218 (90.8)98 (89.1)58 (95.1)40 (88.9)22 (91.7)
≥222 (9.2)12 (10.9)3 (4.9)5 (11.1)2 (8.3)
Menopausal status0.4700.285
Premenopause82 (34.2)32 (29.1)21 (34.4)21 (46.7)8 (33.3)
Postmenopause158 (65.8)78 (70.9)40 (65.6)24 (53.3)16 (66.7)
Prior operation0.0510.032
Surgery183 (76.2)93 (84.5)44 (72.1)34 (75.6)12 (50.0)
Without surgery57 (23.8)17 (15.5)17 (27.9)11 (24.4)12 (50.00)
Number of lines of prior therapies in the advanced setting0.0200.032
182 (34.2)31 (28.2)28 (45.9)11 (24.4)12 (50.0)
≥2158 (65.8)79 (71.8)33 (54.1)34 (75.6)12 (50.0)
ER status0.1550.781
Negative202 (84.2)88 (80.0)54 (88.5)40 (88.9)20 (83.3)
Positive38 (15.8)22 (20.0)7 (11.5)5 (11.1)4 (16.7)
PR status0.1351.000
Negative215 (89.6)103 (93.6)53 (86.9)38 (84.4)21 (87.5)
Positive25 (10.4)7 (6.4)8 (13.1)7 (15.6)3 (12.5)
HER2 status0.4680.652
Negative225 (93.8)102 (92.7)59 (96.7)41 (91.1)23 (95.8)
Positive15 (6.2)8 (7.3)2 (3.3)4 (8.9)1 (4.2)
Molecular subtype0.6650.915
HR+/HER2−43 (17.9)18 (16.4)10 (16.4)10 (22.2)5 (20.8)
HER2+15 (6.3)8 (7.3)2 (3.3)4 (8.9)1 (4.2)
TNBC182 (75.8)84 (76.4)49 (80.3)31 (68.9)18 (75.0)
Molecular subtype group0.5500.594
Non-TNBC58 (24.2)26 (23.6)12 (19.7)14 (31.1)6 (25.0)
TNBC182 (75.8)84 (76.4)49 (80.3)31 (68.9)18 (75.0)
Ki670.7081.000
≤2018 (7.5)6 (5.5)5 (8.2)5 (11.1)2 (8.3)
 >20222 (92.5)104 (94.5)56 (91.8)40 (88.9)22 (91.7)
dNLR*0.1720.964
<2.38104 (43.3)44 (40.0)31 (50.8)19 (42.2)10 (41.7)
≥2.38136 (56.7)66 (60.0)30 (49.2)26 (57.8)14 (58.3)
LDH0.197
≤250141 (58.8)61 (55.5)40 (65.6)25 (55.6)15 (62.5)0.578
 >25099 (41.2)49 (44.5)21 (34.4)20 (44.4)9 (37.5)
ALB0.2200.881
<4096 (40.0)54 (49.1)24 (39.3)12 (26.7)6 (25.0)
≥40144 (60.0)56 (50.9)37 (60.7)33 (73.3)18 (75.0)
Combined immunotherapy regimen0.5300.112
Immunotherapy+chemotherapy127 (52.9)56 (50.9)28 (45.9)25 (55.6)18 (75.0)
Immunotherapy+antiangiogenic therapy±chemotherapy113 (47.1)54 (49.1)33 (54.1)20 (44.4)6 (25.0)
Visceral metastasis0.0160.753
No104 (43.3)42 (38.2)35 (57.4)17 (37.8)10 (41.7)
Yes136 (56.7)68 (61.8)26 (42.6)28 (62.2)14 (58.3)
Number of metastatic sites0.0010.356
1, 2122 (50.8)46 (41.8)41 (67.2)21 (46.7)14 (58.3)
≥3118 (49.2)64 (58.2)20 (32.8)24 (53.3)10 (41.7)
  • Data were presented as number of patients; data in parentheses were percentages unless otherwise noted*value refer to the optimal threshold of dNLR using the maximum Youden Index method

  • ALB, serum albumin; dNLR, derived neutrophil-to-lymphocyte ratio; ECOG, Eastern Cooperative Oncology Group; ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; HR, hormone receptor; LDH, lactate dehydrogenase; PR, progesterone receptor; TNBC, triple-negative breast cancer.